Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

Endoscopic gastric remodeling reduced GERD symptoms and dependence on proton pump inhibitors in patients with obesity, according to a new study.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

Sarcopenic obesity, a hidden condition affecting people over 40, causes muscle loss and fat gain without major weight changes ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...